FOSAMAX is indicated in adults for the treatment of postmenopausal osteoporosis. It reduces the risk of vertebral and hip fractures.
Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC)
The FDA has approved Binosto (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of Osteoporosis in postmenopausal...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
Janssen Research & Development announced data from the pivotal phase III LATITUDE clinical trial, which showed Zytiga (abiraterone acetate) plus...
BMS has announced for the first time interim results from the global, D-LITE Phase IIb study, in which a 24-week...
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy...